Aligos Therapeutics, INC Schedule 13G passive stakes

Woodline Partners LP has disclosed a beneficial ownership of 4.4% in Aligos Therapeutics, Inc., holding 239,362 shares, including exercisable warrants.

Sio Capital Management, LLC reported a 5.46% beneficial ownership stake in Aligos Therapeutics, Inc. as of December 31, 2025.

Woodline Partners LP has filed an amended Schedule 13G, reporting an 8.7% beneficial ownership of Aligos Therapeutics, Inc.'s common stock as of September 30, 2025.

Woodline Partners LP has disclosed a 9.8% passive ownership stake in Aligos Therapeutics, Inc., holding 518,300 shares of common stock.

Sio Capital Management, LLC has disclosed a 5.49% beneficial ownership stake in Aligos Therapeutics, Inc., holding 355,937 shares of common stock.

Adage Capital Management and its principals have filed an amended Schedule 13G, disclosing a 3.90% beneficial ownership in Aligos Therapeutics, Inc.

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has reported a 9.99% beneficial ownership stake in Aligos Therapeutics, Inc. as of March 31, 2025, primarily for passive investment purposes.

EcoR1 Capital, LLC and its affiliates have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of Aligos Therapeutics, Inc. common stock to 3.9% as of March 31, 2025.

Woodline Partners LP has filed a Schedule 13G, reporting a 5.2% beneficial ownership stake in Aligos Therapeutics, Inc. as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Aligos Therapeutics, Inc. as of December 31, 2024.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 9.38% in Aligos Therapeutics, Inc.'s Voting Common Stock.